← board
ONCO
distress 10/10 · high distress / dilution risk$0.87-1%today-100% from 52w high
Lead: prostate cancer · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$4M
Runway
0.4 yrs
Shares 1y
+642%
Price & events
-98.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.5%
1D
+9.5%
1W
-19.0%
1M
-87.0%
3M
-98.9%
6M
-99.5%
1Y
-100.0%
2Y
—
5Y
-100.0%
All
Overview
- Market Cap
- $9.94M
- Volume
- 39.74K
- 52 Week Range
- $0.76 – $242
- Total Shares
- 11.46M
- Float Shares
- 1.15M
- Short %
- 1.67%
- % Held by Insiders
- 0.18%
- % Held by Institutions
- 0.06%
- RVOL
- 0.05x
- Beta
- 2.68
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 5
- Q1 2026trial initiationsecondaryProclarix · Initiated multi-center clinical validation study with Labcorp, enrolling up to 500 men.SEC 8-K
- 2025-09-17partnershipPancreaSure · Proteomedix licensed master cell lines and IP for three biomarkers to Immunovia for $700k total payments plus royalties.SEC 8-K
- 2025-04-14warning letterNasdaq determined stock had bid price ≤$0.10 for ten consecutive days, triggering delisting procedures unless hearing requested.SEC 8-K
- 2025-04-08partnershipSigned non-binding letter of intent for business combination with OcuvexSEC 8-K
- March 23, 2025conferencedata presentationsecondaryProclarix · Clinical performance data presented at EAU 2025 congressSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — prostate cancer
Recent news
- 2026-07-21Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Stud - GlobeNewswire
- 2026-07-21Market Movers | Winners: ADVB, LVLU, ONCO | Losers: QMLS, DARE, PLAG - Trefis
- 2026-07-20Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform - Business Wire
- 2026-07-20Why Is Onco Micro-Cap Stock Surging 50% In Premarket? - Stocktwits
- 2026-07-20Onconetix (ONCO) stock surges over 23% overnight: Why is it moving? - MSN
- 2026-07-18Thule 2bike rack fits towbar R1350 onco - Bike Hub
- 2026-07-17REPL, HOTH, ONCO stocks hit 52-week lows: What's driving the selloff in these biotech plays? - MSN
- 2026-07-16Onco-Innovations starts ADME studies to advance cancer drug ONC010 toward clinical trials - Pluang
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.